Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 2
2010 1
2011 1
2012 2
2013 3
2014 2
2016 2
2017 1
2018 2
2019 4
2020 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
The Prevalence Of Osteoporosis Is Low In Adult Cutaneous Mastocytosis Patients.
Degboé Y, Severino-Freire M, Couture G, Apoil PA, Gaudenzio N, Hermine O, Ruyssen-Witrand A, Paul C, Laroche M, Constantin A, Livideanu CB. Degboé Y, et al. Among authors: livideanu cb. J Allergy Clin Immunol Pract. 2024 Feb 27:S2213-2198(24)00195-8. doi: 10.1016/j.jaip.2024.02.021. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38423295 Free article.
3D deconvolution of human skin immune architecture with Multiplex Annotated Tissue Imaging System.
Scholaert M, Houmadi R, Martin J, Serhan N, Tauber M, Braun E, Basso L, Merle E, Descargues P, Viguier M, Lesort C, Chaput B, Kanitakis J, Jullien D, Livideanu CB, Lamant L, Pagès E, Gaudenzio N. Scholaert M, et al. Among authors: livideanu cb. Sci Adv. 2023 Jun 9;9(23):eadf9491. doi: 10.1126/sciadv.adf9491. Epub 2023 Jun 7. Sci Adv. 2023. PMID: 37285432 Free PMC article.
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.
Chasset F, Jaume L, Mathian A, Abisror N, Dutheil A, Barbaud A, Kottler D, Girard C, Jousse-Joulin S, Tauber M, Livideanu CB, Avettand-Fenoel V, Lhote R, Pha M, Amoura Z; EMSED (Etude des maladies systémiques en dermatologie) study group. Chasset F, et al. Among authors: livideanu cb. J Am Acad Dermatol. 2023 Jul;89(1):171-173. doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5. J Am Acad Dermatol. 2023. PMID: 36878316 No abstract available.
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.
Rossignol J, Ouedrani A, Livideanu CB, Barete S, Terriou L, Launay D, Lemal R, Greco C, Frenzel L, Meni C, Bodemere-Skandalis C, Polivka L, Collange AF, Hachichi H, Bouzourine S, Messaoud DN, Negretto M, Vendrame L, Jambou M, Gousseff M, Durupt S, Lega JC, Durand JM, Gaudy C, Damaj G, Gourin MP, Hamidou M, Bouillet L, Le Mouel E, Maria A, Zunic P, Cabrera Q, Vincent D, Lavigne C, Riviere E, Gourguechon C, Courbebaisse M, Lebeaux D, Parfait B, Friedlander G, Brignier A, Lhermitte L, Molina TJ, Bruneau J, Agopian J, Dubreuil P, Ranta D, Mania A, Arock M, Staropoli I, Tournilhac O, Lortholary O, Schwartz O, Chatenoud L, Hermine O. Rossignol J, et al. Among authors: livideanu cb. J Allergy Clin Immunol Pract. 2022 May;10(5):1356-1364.e2. doi: 10.1016/j.jaip.2021.12.038. Epub 2022 Jan 21. J Allergy Clin Immunol Pract. 2022. PMID: 35074600 Free PMC article.
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T, Arnulf B, Bouaziz JD, Livideanu CB, Osio A, Servy A, Cribier B, Sassolas B, Jachiet M, Michel L, Aucouturier P, Lipsker D, Frances C, Sbidian E, Rybojad M, Descamps V, D'Incan M, Humbert P, Beylot-Barry M, Passeron T, de Moreuil C, Taha RY, Hermine O, Dupuy A, Barbarot S, Debarbieux S, Carpentier O, Brault F, Schmutz JL, Thomas-Beaulieu D, Modiano P, Zarnitsky C, Lifermann F, Baubion E, Limal N, Le Bras F, Le Moigne M, Tauber M, Talbot A, Prud'homme R, Peltier S, De Masson A, Battistella M, Bagot M, Mékinian A, Fain O. Mahévas T, et al. Among authors: livideanu cb. Blood. 2020 Apr 2;135(14):1101-1110. doi: 10.1182/blood.2019002300. Blood. 2020. PMID: 32027747 Free article.
Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, Barete S, Canioni D, Lhermitte L, Rossignol J, Arock M, Dubreuil P, Lortholary O, Hermine O. Lemal R, et al. Among authors: livideanu cb. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2387-2395.e3. doi: 10.1016/j.jaip.2019.03.039. Epub 2019 Apr 5. J Allergy Clin Immunol Pract. 2019. PMID: 30954641 Clinical Trial.
Combining Omalizumab with Another Biotherapy.
Fougerousse AC, Becherel PA, Pallure V, Boyé T, Reguiai Z, Gabison G, Barthelemy H, Badaoui A, Mahé E, Livideanu CB; GEM ResoPso. Fougerousse AC, et al. Among authors: livideanu cb. Acta Derm Venereol. 2019 Apr 1;99(4):448-449. doi: 10.2340/00015555-3140. Acta Derm Venereol. 2019. PMID: 30723874 Free article. No abstract available.
24 results